Investment objective & strategy
As of April 28, 2025 · prospectusObjective. Driehaus Micro Cap Growth Fund seeks to maximize capital appreciation.
Strategy. The Fund uses a growth style of investment in equity securities, including common stocks and other equity securities of issuers. Under normal market conditions, the Fund invests at least 80% of its net assets (plus the amount of borrowings for investment purposes) in the equity securities of U.S. micro-capitalization (micro-cap) companies. For purposes of the Fund, the investment adviser considers a company to be a micro-cap company if it is within the same market capitalization range at the time of investment as those included in the Russell Microcap Growth Index. For the avoidance of doubt, while the reference index is float-adjusted, meaning it excludes closely held and other shares unavailable to investors, the investment adviser does not consider a float-adjustment … The Fund uses a growth style of investment in equity securities, including common stocks and other equity securities of issuers. Under normal market conditions, the Fund invests at least 80% of its net assets (plus the amount of borrowings for investment purposes) in the equity securities of U.S. micro-capitalization (micro-cap) companies. For purposes of the Fund, the investment adviser considers a company to be a micro-cap company if it is within the same market capitalization range at the time of investment as those included in the Russell Microcap Growth Index. For the avoidance of doubt, while the reference index is float-adjusted, meaning it excludes closely held and other shares unavailable to investors, the investment adviser does not consider a float-adjustment when determining the market capitalization of a company. As of March 31, 2025, approximately 89% of the Russell Microcap Growth Index consisted of companies with a market capitalization of less than $2 billion. Securities of companies whose market capitalization no longer meets this definition after purchase may continue to be held by the Fund. In addition, while the Fund will invest primarily in the equity securities of U.S. micro-cap companies, the Fund may also from time to time invest up to a maximum of 20% of its assets in the equity securities of non-U.S. companies that trade in the U.S. (such as American Depositary Receipts (ADRs) or substantially similar instruments that are based on foreign securities) or in securities of companies above the capitalization range of the Russell Microcap Growth Index. The Fund may invest in companies with limited or no operating histories. The Fund frequently and actively trades its portfolio securities. Investment decisions for the Funds growth style of investing are based on the belief that fundamentally strong companies are more likely to generate superior earnings growth on a sustained basis and are more likely to experience positive earnings revisions. These decisions involve evaluating a companys competitive position, evaluating industry dynamics, identifying potential growth catalysts and assessing the financial position of the company. The decision is also informed by the evaluation of relative valuation, macroeconomic and behavioral factors affecting the company and its stock price. The Fund sells holdings for a variety of reasons, including to take profits, changes to the fundamental investment thesis, changes in the risk/reward assessment of the holding, an assessment that the holding is efficiently priced, to make room for more attractive ideas or for other portfolio or risk management considerations.
Top holdings
As of March 31, 2026 · N-PORT| Security | Ticker | Value | % of fund |
|---|---|---|---|
| PRAXIS PRECISION MEDICINES INC | — | $11.93M | 2.61% |
| APPLIED OPTOELECTRONICS INC | — | $10.12M | 2.21% |
| Northern Institutional Funds GOVT SELECT PT | BGSXX | $10.01M | 2.19% |
| PLANET LABS PBC A | — | $8.41M | 1.84% |
| NLIGHT INC | — | $7.77M | 1.70% |
| TERAWULF INC | — | $7.58M | 1.65% |
| AMPRIUS TECHNOLOGIES INC | — | $7.20M | 1.57% |
| SPYRE THERAPEUTICS INC | — | $6.85M | 1.50% |
| XENON PHARMACEUTICALS INC | — | $6.63M | 1.45% |
| CRINETICS PHARMACEUTICALS INC | — | $6.37M | 1.39% |
Portfolio moves
Dec 31, 2025 → Mar 31, 2026How many positions this fund opened, exited, grew, trimmed, or left unchanged between its two most recent N-PORT snapshots — net changes between point-in-time reports, not a trade log.
Similar funds
Funds whose portfolios most overlap this one, by weight| Fund | Overlap | Net exp. |
|---|---|---|
| Driehaus Small Cap Growth Fund · DVSMX, DNSMX | 35% | 0.70% |
| Adara Smaller Companies Fund | 32% | 0.80% |
| 1290 VT Micro Cap Portfolio | 25% | 0.90% |
Advisers
| Firm | Role |
|---|---|
| Driehaus Capital Management LLC | Adviser |
Footnotes
- Expense ratio as of April 28, 2025, from the fund's prospectus.
- Net assets and holdings count as of March 31, 2026, from the fund's N-PORT filing.
- Total return for calendar year 2025, before tax and after fund expenses. Computed by compounding the twelve monthly total returns the fund reported in its SEC N-PORT filings for 2025 (the latest prospectus does not yet chart this year).
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.